Filtered By:
Drug: Aspirin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 5437 results found since Jan 2013.
Aspirin exacerbated respiratory disease: the search for a biomarker.
PMID: 25442693 [PubMed - in process]
Source: Annals of Allergy, Asthma and Immunology - November 1, 2014 Category: Allergy & Immunology Authors: Cahill KN, Laidlaw TM Tags: Ann Allergy Asthma Immunol Source Type: research
Using Age-Related Gene Expression Changes to Search for Drugs to Slow Aging
In this study, using gene expression data for human brain ageing, we aimed to discover not only new pro-longevity drugs but also those that can improve health during ageing. The biological processes showing a change in expression include pathways related to synaptic and cognitive functions as well as proteostasis, suggesting gene expression changes in the ageing brain could be used as a surrogate to find drugs to target detrimental effects.
Using multiple gene expression datasets from brain tissue, taken from patients of different ages, we first identified the expression changes that characterise ageing. Then, we c...
Source: Fight Aging! - July 2, 2018 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
Conditions: Atrial Fibrillation; Antithrombotic Therapy; Acute Coronary Syndrome; Percutaneous Coronary Interventions Interventions: Drug: Ticagrelor; Drug: Dabigatran Etexilate; Drug: Aspirin; Drug: Clopidogrel Sponsors: Medical University of Gdansk; Medical University of Warsaw; Nicolaus Copernicus University; Institute of Cardiology, Warsaw, Poland; Military Institute of Medicine, Poland; Bielanski Hospital; Medical University of Silesia; Poznan University of Medical Sciences; University of Opole, Poland; Medical University of...
Source: ClinicalTrials.gov - January 5, 2021 Category: Research Source Type: clinical trials
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
CONCLUSIONS: The certainty of the available evidence for the comparative effects of ASA, VKA, LMWH, and DOAC on all-cause mortality, DVT, PE, or bleeding was either low or very low. People with multiple myeloma considering antithrombotic agents should balance the possible benefits of reduced thromboembolic complications with the possible harms and burden of anticoagulants. Editorial note: This is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Da...
Source: Cochrane Database of Systematic Reviews - September 28, 2021 Category: General Medicine Authors: Lara A Kahale Charbel F Matar Ibrahim Tsolakian Maram B Hakoum Victor Ed Yosuico Irene Terrenato Francesca Sperati Maddalena Barba Lisa K Hicks Holger Sch ünemann Elie A Akl Source Type: research
Interventions for preventing thrombosis in solid organ transplant recipients
CONCLUSIONS: Overall, there is a paucity of research in the field of graft thrombosis prevention. Due to a lack of high quality evidence, it remains unclear whether any therapy is able to reduce the rate of early graft thrombosis in any type of solid organ transplant. UFH may increase the risk of major bleeding in kidney transplant recipients, however this is based on low certainty evidence. There is no evidence from RCTs to guide anti-thrombotic strategies in liver, heart, lung, or other solid organ transplants. Further studies are required in comparing anticoagulants, antiplatelets to placebo in solid organ transplantati...
Source: Cochrane Database of Systematic Reviews - March 15, 2021 Category: General Medicine Authors: Vignesh Surianarayanan Thomas J Hoather Samuel J Tingle Emily R Thompson John Hanley Colin H Wilson Source Type: research
Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents
CONCLUSIONS: The certainty of the available evidence for the comparative effects of ASA, VKA, LMWH, and DOAC on all-cause mortality, DVT, PE, or bleeding was either low or very low. People with multiple myeloma considering antithrombotic agents should balance the possible benefits of reduced thromboembolic complications with the possible harms and burden of anticoagulants. Editorial note: This is a living systematic review. Living systematic reviews offer a new approach to review updating in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Da...
Source: Cochrane Database of Systematic Reviews - September 28, 2021 Category: General Medicine Authors: Lara A Kahale Charbel F Matar Ibrahim Tsolakian Maram B Hakoum Victor Ed Yosuico Irene Terrenato Francesca Sperati Maddalena Barba Lisa K Hicks Holger Sch ünemann Elie A Akl Source Type: research
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia
CONCLUSIONS: We found no convincing evidence to suggest any clinically relevant cognitive benefit of using antithrombotic therapy in addition to standard treatment in people with cerebral small vessel disease but without dementia, but there may be an increased bleeding risk with this approach. There was marked heterogeneity across the trials and the certainty of the evidence was generally poor.PMID:35833913 | PMC:PMC9281623 | DOI:10.1002/14651858.CD012269.pub2
Source: Cochrane Database of Systematic Reviews - July 14, 2022 Category: General Medicine Authors: Joseph Kwan Melanie Hafdi Lorraine L W Chiang Phyo K Myint Li Siang Wong Terry J Quinn Source Type: research
